Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Change in Receivables (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Change in Receivables data on record, last reported at $151000.0 in Q3 2025.

  • For Q3 2025, Change in Receivables fell 98.48% year-over-year to $151000.0; the TTM value through Sep 2025 reached -$10.0 million, down 206.69%, while the annual FY2024 figure was -$397000.0, 85.59% up from the prior year.
  • Change in Receivables reached $151000.0 in Q3 2025 per SGMO's latest filing, up from $6000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $9.9 million in Q3 2024 and bottomed at -$10.0 million in Q4 2024.
  • Average Change in Receivables over 5 years is -$247421.1, with a median of -$160000.0 recorded in 2025.
  • The widest YoY moves for Change in Receivables: up 732.33% in 2024, down 4331.11% in 2024.
  • A 5-year view of Change in Receivables shows it stood at -$2.0 million in 2021, then skyrocketed by 56.81% to -$844000.0 in 2022, then surged by 73.34% to -$225000.0 in 2023, then crashed by 4331.11% to -$10.0 million in 2024, then surged by 101.51% to $151000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $151000.0 in Q3 2025, $6000.0 in Q2 2025, and -$160000.0 in Q1 2025.